FIS
ENGN icon

FCPM III Services’s enGene Therapeutics ENGN Stock Holding History

FCPM III Services’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7M Hold
9,632,561
– – 2.22% 9
2026
Q1 		$65.6M Hold
9,632,561
– – 9.08% 4
2025
Q4 		$87M Hold
9,632,561
– – 11.4% 3
2025
Q3 		$65.8M Hold
9,632,561
– – 13.15% 3
2025
Q2 		$35.1M Hold
9,632,561
– – 9.5% 4
2025
Q1 		$43.2M Hold
9,632,561
– – 10.43% 3
2024
Q4 		$64.1M Buy
9,632,561
+954,610
+11% +$7.41M 10.81% 3
2024
Q3 		$57.3M Hold
8,677,951
– – 9.84% 3
2024
Q2 		$81.8M Hold
8,677,951
– – 12.07% 3
2024
Q1 		$147M Hold
8,677,951
– – 20.79% 3
2023
Q4 		$80.1M Buy
+8,677,951
New +$76.8M 23.6% 3

Other funds holding ENGN

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

FCPM III Services's ENGN Position: Q2 2026 in Review

FCPM III Services held its enGene Therapeutics (ENGN) position steady in Q2 2026 at 9,632,561 shares worth $16.7M. The position accounts for 2.22% of the portfolio, ranked #9.

FCPM III Services first reported a position in ENGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $147M in Q1 2024. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • FCPM III Services held 9,632,561 shares of enGene Therapeutics worth $16.7M as of Q2 2026.
  • FCPM III Services left its enGene Therapeutics share count unchanged in Q2 2026.
  • enGene Therapeutics made up 2.22% of FCPM III Services's portfolio in Q2 2026, its #9 holding.
  • FCPM III Services first reported a position in enGene Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • FCPM III Services's enGene Therapeutics position peaked at $147M in Q1 2024.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on FCPM III Services's 13F filing for Q2 2026, filed 14 Aug 2026.